



Market Announcement

3 December 2024

Acrux Limited (ASX: ACR) – Trading Halt

Description

The securities of Acrux Limited ('ACR') will be placed in trading halt at the request of ACR, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Thursday, 5 December 2024 or when the announcement is released to the market.

Issued by

ASX Compliance

For personal use only



ASX Release

3 December 2024

Request for Trading Halt

Melbourne, Australia; Acrux Limited (ASX:ACR)

Pursuant to Listing Rule 17.1, Acrux Limited (the Company or Acrux) requests that ASX grants an immediate trading halt for its ordinary shares.

In accordance with Listing Rule 17.1, the Company advises that:

- the trading halt is requested to enable Acrux to finalise details of a proposed capital raising;
- Acrux requests that the trading halt remain in place until the earlier of such time as it makes an announcement to the market in relation to a proposed capital raising and the commencement of trading on 5 December 2024; and
- Acrux is not aware of any reason why the trading halt should not be granted or of any other information necessary to inform the market or ASX about the trading halt.

This announcement has been authorised for release to the ASX by the Board of Directors.

For more information, please contact:

Michael Kotsanis
CEO & Managing Director
E: michael.kotsanis@acrux.com.au

Joanna Johnson
CFO & Company Secretary
E: joanna.johnson@acrux.com.au

P: + 61 3 8379 0100

About Acrux

Acrux is a specialty pharma company with a successful track record of developing and commercialising a pipeline of topically applied pharmaceutical products. Drawing on 25 years of experience, Acrux has successfully marketed through licensees a number of products worldwide with emphasis on the United States. Acrux is formulating and developing a range of topical generic products by leveraging its highly skilled workforce, on-site laboratories, GMP manufacturing suite, technical, clinical and commercial experience to bring affordable products to market. Acrux encourages collaboration and is well positioned to discuss commercial partnering and product development opportunities. For further information on Acrux, visit: www.acrux.com.au

For personal use only